Studying PSMA imaging in glioblastoma with bevacizumab
Part of Cancer clinical trials.
This trial tests whether adding a special imaging scan (PSMA PET) before and after the drug bevacizumab can help see how the drug affects glioblastoma tumors. It aims to understand tumor changes better, which may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of brain tumor called glioblastoma (IDH wildtype)
- You finished radiation therapy at least 1 month ago and there is still some tumor
- Your doctor plans to treat you with the drug bevacizumab
- You are in generally good health (able to walk and care for yourself) and no major organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood test markers that may predict who survives at 6 months after starting bevacizumab for glioblastoma that has come back. It does not aim to cure the cancer by itself, but to improve doctors’ ability to choose the most helpful treatment plan.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial uses special MRI scans and a contrast agent to look at the immune environment of glioblastoma tumors. It may help doctors learn more about how the tumor responds to treatment.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.